What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%



Code Company Date Close Change Indicator Value Signal

Trading Performance

Weighted Moving Average



Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 47 8.2 0.23% 0.30% 27.7% -3.2% 186.5%
SHORT 49 8.5 0.29% 0.34% 4.5% -3.1% -63.1%


Technical Analysis

Opthea (OPT.AX)



Last Signal:


Trading: SELL @ $2.73
Signal Strength: STRONG

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.

Opthea (ASX:OPT) currently has a confirmed downtrend. Recent trading has caused the WMA 15 day average to move below the closing price confirming the short term trend following indicator. Currently, the return on WMA15 is -6.2%.

Weighted moving averages (WMA) are difficult to construct but more reliable than the simple moving averages. WMA permits an unequal weighting on prior time periods.

Calculation: Weighted Moving Average (WMA):
1) Ft= W1At-1 + WnAt-n


Stock Exchange: ASX
Company: Opthea
Ticker Codes: | OPT.AX | ASX:OPT |

About Opthea (ASX:OPT):

Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.

Top 10:

Weighted Moving Average

Company Close Change(%) Volume Value Signal
SVW Seven Holdings 19.15 -0.3 368,012 0 BEARISH CROSSOVER
LIC Lifestyles Communities 8.26 -0.4 64,094 0 BEARISH CROSSOVER
MLT Milton Corporation 4.83 -0.4 115,637 -0.1 BEARISH CROSSOVER
SGM Sims 10.79 -0.4 435,082 -0.2 BEARISH CROSSOVER
TAH Tabcorp Holdings 4.79 -0.6 12,447,005 -0.1 BEARISH CROSSOVER
BAF Blue Sky Alternatives 0.9 -0.6 134,512 -0.2 BEARISH CROSSOVER
BRG Breville 17.17 -0.6 108,068 -0.2 BEARISH CROSSOVER
ERF Elanor Retail Property Fund 1.23 -0.8 10,000 -0.5 BEARISH CROSSOVER
BTI Bailador Technology Investments 1.01 -1 73,825 -0.6 BEARISH CROSSOVER
NCM Newcrest Mining 30.76 -1 2,623,793 -0.4 BEARISH CROSSOVER